Cost Analysis of Ertapenem Therapy for Urinary Tract Infections and Assessment of Its Suitability for Outpatient Parenteral Antibiotic Therapy Programme in Turkey
Journal Title: Mediterranean Journal of Infection, Microbes and Antimicrobials - Year 2017, Vol 6, Issue 1
Abstract
Introduction: The primary aim of this study was to evaluate whether there was a difference between outpatient parenteral antibiotic therapy (OPAT) and inpatient parenteral antibiotic therapy (IPAT) costs of ertapenem for urinary tract infections (UTI’s) due to extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacilli, and to discuss suitability of ertapenem for OPAT programme of Turkey for the near future. Materials and Methods: A total of 53 patients hospitalized with the diagnosis of UTI and treated with ertapenem were retrospectively evaluated. The cost of ertapenem treatment as IPAT was actual costs retrieved from the hospital records. The estimated cost of the same antibiotic for the same patients as an OPAT programme was then calculated and the costs were compared. Results: The cost difference between IPAT and OPAT was ₺ 12.305 (€ 5783). Outpatient parenteral antibiotic therapy programme would provide an estimated 20% reduction in treatment costs. The estimated number of bed days saved, if the patients had received the treatment as OPAT, was calculated to be 583 days, which constitutes about 5% of the total number of hospitalization days. Conclusion: Applying ertapenem therapy through OPAT programme for UTIs caused by ESBL-producing Gram-negative bacilli will decrease the financial burden of health expenditures and the number of inpatient bed days in Turkey.
Authors and Affiliations
Bahar ÖRMEN, Nesrin TÜRKER, Nurbanu SEZAK, Zerrin KARA, Figen KAPTAN, Tuna DEMİRDAL, Melih Kaan SÖZMEN
Keywords
Related Articles
- EP ID EP689352
- DOI 10.4274/mjima.2017.7
- Views 133
- Downloads 0
Misleading Radiological Appearances for Fever of Unknown Origin: Beyond Terminal Ileitis
No Abstract
Current Status in Middle East Respiratory Syndrome Coronavirus
Middle East respiratory syndrome coronavirus (MERS-CoV) which was first described in 2012, belongs to the CoV family. Coronaviruses may cause global outbreaks with high mortality. Although there is no definite evidence,...
Cefoxitin: Interesting Perspectives on a Neglected Intravenous Beta-lactam
Cefoxitin is a beta-lactam antibiotic belonging to the cephamycins class, up to now only used in clinical practice for prophylaxis during surgery. Recently, its use has increased due to the spread of infections caused by...
EDİTÖRYAL
No Abstract
Comparison between Cefoxitin Disc Diffusion and Phoenix Automated System with mecA/mecC PCR for Determination of Methicillin Resistance in Staphylococcus aureus Isolates and Investigation of the Presence of PVL Gene
Introduction: A fast and accurate determination of methicillin resistance in Staphylococcus aureus strains is vital. This study aimed to compare the sensitivity and specificity of the cefoxitin disc diffusion (CDD) test...